Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) is forging ahead with its mission to revolutionize cancer treatment, announcing today the acceler...
Backed by their common shareholder, Keensight Capital, one of the leading private equity funds dedicated to pan-European Growth Buyout[] investments, the c...
Carcinotech has raised $5.3 million of funding as the company looks to build on its traction in the UK and Europe, with US expansion planned later this yea...
Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multi...
The three partners are joining forces to develop drug candidates that modulate the immune response of cancer patients and block the development of metast...
Under a collaboration with LGC Biosearch TechnologiesTM, RevoluGen has coupled its Fire Monkey chemistry with LGC magnetic beads and LGC oKtopureTM liquid ...
Prostate.Carcinoma.ai“ significantly aids radiologists by automatically segmenting the prostate gland in MRI scans and independently identifying path...
Embracing the latest technology trends, LPH 1.0 represents a significant leap forward, with an upgrade to HTML5 browser-based technology. This advancement ...
Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma. Over the past few years, Vivtex has...
Glass vials are regularly used for pharmaceutical packaging, though there is a growing market need for primary packaging that is suited to more sensitive, ...
Thermo Fisher Scientific, the world leader in the service of science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Ag...
The newly granted patent, EP3927337, which will have an effective date of February 14, 2024, and an expiry date of no earlier than 2040, is expected to cov...
Menarini Silicon Biosystems, a pioneer of liquid biopsy and single-cell technologies, announced the recent publication of the STIC CTC trial data demonstra...
New investment from DRW Venture Capital LLC and Tolmar International Ltd Funds will be used to advance its proprietary, silica-based, drug delivery...
© 2024 Biopharma Boardroom. All Rights Reserved.
